Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good to hold on to those 100k shares. Hope Leny's predictions of a sharp merger premium are accurate.
Porscha, Are these among the Siemens patents? TIA
7 is right above 4 on my keyboard numeric pad. Someone probably just had a "fat" finger putting in the order.
Good analysis FUN.
Yup, still alive and kicking. Buy some ROX on occassion too. Buying more Jeffersons than before.
Johnny and FUN,
Remember those old CERTS commercials with two twins arguing whether CERTS are a candy mint or a breath mint?
You are both right in different respects. If ROX made $5,000 in a year - but issued enough shares to double the shares outstanding - and that amounted to one-tenth of a cent positive GAAP income per share before the increased number of shares, the added shares would drive the GAAP income per share down to one-twentieth of a cent. Both would be shown as $0.00.
Johnny is right in that added shares ARE dilutive and that the numbers per share are even less impressive.
Funman is right in that both numbers would still be GAAP black.
Welcome back Meister!
And we had a nice reaction in the share price and with upgraded ratings by brokerages. GLTAL
FUN, you beat me to it.
Castle Brands Announces Fiscal 2017 Third Quarter Results
Gross Profit Increased 14.4% on Net Sales Increase of 6.4%
Driven by Continued Strong Growth of Jefferson's, Goslings, and Irish whiskey portfolios
NEW YORK, Feb. 9, 2017 /PRNewswire/ -- Castle Brands Inc. (NYSE MKT: ROX), a developer and international marketer of premium and super-premium branded spirits, today reported financial results for the three and nine months ended December 31, 2016.
Operating highlights for the quarter ended December 31, 2016:
Net sales increased 6.4% to $18.3 million for the third quarter of fiscal 2017, as compared to $17.2 million for the comparable prior-year period.
Total gross profit increased 14.4% to $7.7 million, as compared to $6.7 million for the comparable prior-year period.
Net income attributable to common shareholders of $0.4 million versus a loss of ($0.8) million for the comparable prior-year period.
EBITDA, as adjusted, improved by 132.1% to $1.6 million, as compared to $0.7 million in fiscal 2016.
Continued strong growth of Jefferson's bourbons and the Irish whiskies led to a 14.5% increase in whiskey revenues from the comparable prior-year period.
Goslings Stormy Ginger Beer case sales increased 42.9% to approximately 339,000 cases from approximately 237,000 in the comparable prior-year period.
In addition to continuing its new fill programs, the Company purchased an additional 1,000 barrels of aged bourbon to support the continued growth of Jefferson's.
The Company entered into five-year exclusive distribution agreement for The Arran Malt Single Malt Scotch Whisky and Robert Burns Single Malt Whisky and Blended Scotch Whisky in the US market.
"Continued strong growth of our more profitable brands, such as Jefferson's and our Irish whiskeys, resulted in solid revenue growth and even greater growth in gross profit. This allowed us to increase income from operations, report net income and increase EBITDA, as adjusted. We expect these trends of increasing sales and improving financial performance to continue over the balance of the fiscal year and beyond," stated Richard J. Lampen, President and Chief Executive Officer of Castle Brands.
"The combination of our new fill whiskey program, coupled with opportunistic purchases of aged whiskies, enables us to build our substantial reserves of aged bourbon to support continued strong growth of our Jefferson's brand. The third quarter saw the launch of the Ninth Voyage of our Jefferson's Ocean Aged at Sea® Bourbon, as well as the introduction of Jefferson's Reserve Old Rum Cask Finish and Jefferson's Reserve Pritchard Hill® Cabernet Cask Finish. We plan to expand our wine finishes program and introduce several other new Jefferson's expressions in the coming quarters. We also increased our Irish whiskey offerings and expanded our barrel program for Knappogue Castle Whiskey. We see the Isle of Arran Distillers' award-winning, premium brands as a good complement to our existing whiskies portfolio. We expect to continue to drive strong sales increases for our whiskey portfolio," stated John Glover, Chief Operating Officer of Castle Brands.
Goslings Stormy Ginger Beer sales for the 12 months ended December 31, 2016 exceeded 1.2 million cases, making Goslings Stormy Ginger Beer the best-selling premium ginger beer in America. The growing popularity of ginger beer cocktails, including Goslings' trademarked "Dark 'n Stormy"® cocktail, has been an important growth driver for the brand. We are also increasing the prominence of the Goslings brand through our sponsorship of the 35th America's Cup. The America's Cup has become an extreme sport and millions of viewers are following this very high-profile event. Europe and the United States hosted races in 2015 and 2016 and AC35 will culminate with the Challenger Playoffs and Finals in Bermuda in 2017. Goslings will have far more visibility and global reach than ever before with an enormous audience that goes well beyond the demographics of the sailing world," Mr. Glover added.
For the Three and Nine Months Ended December 31, 2016
For the three months ended December 31, 2016, the Company had net sales of $18.3 million, a 6.4% increase from net sales of $17.2 million in the comparable prior-year period. This sales growth was primarily driven by the U.S. sales growth of Jefferson's bourbons and Goslings Stormy Ginger Beer. Net income was $0.9 million for the three months ended December 31, 2016as compared to a net loss of ($0.6) million in the comparable prior-year period. Net income attributable to common shareholders was $0.4 million, or $0.00 per basic and diluted share, million for the three months ended December 31, 2016, as compared to ($0.8) million, or ($0.01) per basic and diluted share, in the prior-year period.
EBITDA, as adjusted, for the for the three months ended December 31, 2016 improved to $1.6 million as compared to $0.7 million for the comparable prior-year period.
For the nine months ended December 31, 2016, the Company had net sales of $54.7 million, a 4.7% increase from net sales of $52.3 million in the comparable prior-year period. Net loss was ($0.2) million for the nine months ended December 31, 2016, as compared to a net loss of ($2.1) million in the comparable prior-year period. Net loss attributable to common shareholders was ($1.0) million, or ($0.01) per basic and diluted share, for the nine months ended December 31, 2016, as compared to ($2.9) million, or ($0.02) per basic and diluted share, in the prior-year period.
EBITDA, as adjusted, for the nine months ended December 31, 2016 was $3.1 million and $2.2 million for the comparable prior-year period.
From the quarterly report:
OraSure Announces 2016 Fourth Quarter and Full-Year Financial Results
BETHLEHEM, PA – February 8, 2017 – (Globe Newswire) – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2016.
Financial Highlights
• Consolidated net revenues for the fourth quarter of 2016 were $35.5 million, a 10% increase from the fourth quarter of 2015. Consolidated net revenues for the year ended December 31, 2016 rose to $128.2 million, a 7% improvement from 2015.
• Net molecular collection systems revenues were $8.6 million during the fourth quarter of 2016, which represents a 10% increase over the fourth quarter of 2015. Net molecular collection systems revenues for the year ended December 31, 2016 were $32.2 million, an 8% improvement from 2015.
• Net revenues from international sales of the Company’s OraQuick ® HIV products were $1.3 million for the fourth quarter of 2016, representing a 217% increase over the fourth quarter of 2015. Net international HIV revenues were $5.2 million for the year ended December 31, 2016, a 118% increase from 2015.
• International sales of the Company’s OraQuick ® HCV test were $2.9 million for the fourth quarter of 2016, representing a 123% increase from the fourth quarter of 2015. International HCV sales for the year ended December 31, 2016 rose to $6.6 million, a 71% improvement from 2015.
• During the fourth quarter of 2016, the Company made its first shipments of product, worth $1.9 million, under an $18 million supply contract with a foreign government, largely consisting of OraQuick ® HCV tests.
• Consolidated net income for the fourth quarter of 2016 was $7.2 million, or $0.13 per share on a fully-diluted basis, which compares to consolidated net income of $4.6 million, or $0.08 per share on a fully-diluted basis, for the fourth quarter of 2015. Consolidated net income for the year ended December 31, 2016 was $19.7 million, or $0.35 per share on a fully-diluted basis, which compares to consolidated net income of $8.2 million, or $0.14 per share on a fully-diluted basis, for the comparable period of 2015.
• Cash and short-term investments totaled $120.9 million and working capital amounted to $139.1 million at December 31, 2016.
BIVI 10Q is out today. Click in the links above or here:
http://seekingalpha.com/filing/3390463?app=1&uprof=44
PM, I'm convinced those decent quarters are coming, although that earnings curve will be lumpy as all heck.
Thanks PM. This company requires patienceeeeeee.
FUN, Sounds like a nice addition to the $ROX stable of brands. Can't help but be at least modestly accretive to sales and earnings.
PM, Thank you for posting those highlights.
Castle Brands and Isle of Arran Distillers Limited Announce Exclusive Distribution Agreement
BY PR Newswire
— 8:30 AM ET 02/07/2017
NEW YORK, Feb. 7, 2017 /PRNewswire/ -- Castle Brands Inc. , a developer and international marketer of premium and super-premium branded spirits, and Isle of Arran Distillers Limited, a producer of premium quality Single Malt Scotch Whisky, today announced a five-year exclusive distribution agreement for The Arran Malt Single Malt Scotch Whisky and Robert Burns Single Malt Whisky and Blended Scotch Whisky in the US market.
Richard J. Lampen, President and Chief Executive Officer of Castle Brands ( ROX
Loading... Loading...
) said, "The agreement with Isle of Arran Distillers allows us to leverage our distribution platform and our successes with our Jefferson's bourbon portfolio and our expanding Irish whiskey offerings. Adding the Isle of Arran Scotch whiskies sets us apart as a leader in the premium whiskey category."
John Glover, Chief Operating Officer of Castle Brands ( ROX
Loading... Loading...
) said, "Isle of Arran Distillers' award-winning, premium brands perfectly complement our whiskies portfolio. Their exciting range of aged whiskies and finishes will add to the impressive growth of our whiskey brands and strengthen our position in the US market. Our expertise in marketing special finishes of our bourbons and Irish whiskies position us well to distribute Isle of Arran's unique Scotch whisky finishes and special offerings. We look forward to working with them to market these premium Scotch whiskies."
Euan Mitchell, Managing Director of Isle of Arran Distillers Limited said, "We are delighted to be working with Castle Brands ( ROX
Loading... Loading...
) to build our profile in the US market and introduce our award-winning brands to even more whisky aficionados. The Single Malt category continues to develop in the US and Castle Brands ( ROX
Loading... Loading...
) are perfectly poised to leverage further growth for the Arran portfolio using their extensive knowledge and experience. We have many exciting releases planned for the years ahead."
About Castle Brands ( ROX
Loading... Loading...
)
Castle Brands ( ROX
Loading... Loading...
) is a developer and international marketer of premium and super-premium beverage alcohol brands including: Jefferson's®, Jefferson's Presidential SelectTM, Jefferson's Reserve®, Jefferson's Ocean Aged at Sea Bourbon, Jefferson's Wine Finish Collection and Jefferson's Wood Experiments, Goslings® Rums, Knappogue Castle Whiskey®, Clontarf® Irish Whiskey, Pallini® Limoncello, Boru® Vodka and Brady's® Irish Cream. Additional information concerning the Company is available on the Company's website, www.castlebrandsinc.com.
About Isle of Arran Distillers
Isle of Arran Distillers is an independent Distiller of premium quality Single Malt Scotch Whiskies. Located in the village of Lochranza on the beautiful Isle of Arran, the Distillery opened in 1995 and is the only whisky producer on the island. Arran's portfolio includes the classic 10 Years Old, the new 18 Years Old as well as the official Robert Burns whiskies; endorsed by the World Burns Federation. More information is available at www.arranwhisky.com.
It figures. Gotta get thru the hassles of TSA before you can relax at the bar.
It could be a road trip as well. Is the bar inside the TSA perimeter, as I suspect? That would require an airline ticket to get to the bar or a job at the airport.....
Mmmmm. Let's see, fly into Louisville, sample some JPS, go tour the distillery......
$oldier, Is Jeff's Presiidential Select still available now? That article was published in 2013 and any "new" JPS might be an entirely different, less-woody, beast.
1. Jeff's Ocean cask strength (I have voyage 7)
2. Jeff's Ocean (U have to take whichever Voyage u can get, but I have voyage 4)
3. Jeff''s Reserve
All IMHO. Enjoy your search for the best.
History of the Van Winkle brands...from Michael Veach
Pappy 101
I keep hearing people telling me that they picked up “three bottles of Pappy” or five bottles or some other number of bottles and then find out what they have is a couple of bottles of Old Rip Van Winkle 10yo and a Van Winkle Special Reserve 12yo. None of these are “Pappy Van Winkle” Bourbon. Different brands. Different taste profile. I just shake my head in wonder and let it go because they don’t know any better, but there is history to the brand.
Julian P. Van Winkle (Pappy) was one of the three founders of Stitzel-Weller distillery after prohibition. He was the salesman for the three partners and the most publicly recognized face in the company. He also out lived Farnsley and Stitzel by about 15 years. His son, Julian P. Van Winkle, Jr. ran the company after his death until 1972 when the company was sold to Norton-Simon. It was not Julian Jr.’s fault the distillery was sold. It was a combination of circumstances that included the heirs of Stitzel, Farnsley and even his own sister wanted the money instead of the distillery. Who can blame them when Bourbon sales were declining every year and inventories were building up in the warehouses with barrels of Bourbon they could not sell.
Julian Jr., sold the distillery but remained in the business. Part of the sale included a clause that allowed him to purchase barrels of whiskey for bottling his own product. He also purchased barrels from other distilleries such as Yellowstone to fill his decanters. Yes decanters. That was his primary business in the 70s with “Apothecary” decanters decorated for St. Patrick’s Day or college football teams, or any other event that the customer wanted to commemorate. He also revived the “Old Rip Van Winkle” label that had been dormant for years. He bottled The Old Rip Van Winkle as 7 and 8 year old expressions. His son Julian III would change this to 10 yo 90 proof, a 10 yo 107 proof and eventually a 15 yo 107 proof all in the drum shaped bottle with a similar parchment look label. Julian P. Van Winkle III joins his father in the business in 1977 and inherited the company when his father passed away in November 1981.
Julian the third is a true master of whiskey. He knows good whiskey when he tastes it or at least he has many people that share his preference in whiskey. He took his father’s small bottling business and grew it into what it is today, but it was not easy. Julian Jr. had been doing his bottling at the Old Fitzgerald Distillery, but in 1982 that contract ended and Julian III had to find a new home. He purchased the old Hoffman Distillery in Lawrenceburg, Ky. in 1983. Juliann III also expanded the sales in to Japan by supplying whiskey for such brands as Society of Bourbon Connoisseurs and others. Julian III picked many great barrels of bourbon for his brands. He had the advantage of purchasing only what he thought was good whiskey and passing on barrels below his standards. It was not easy and he worked many long hours at his Lawrenceburg bottling hall and barrel rackhouse filling orders and shipping cases.
It was in the late 80s that Julian found a fantastic image of his grandfather and wanted to honor him by using it on a Bourbon label. It took a few years but he finally found the Bourbon for this new brand. He had managed to purchase the last of the Old Boone whiskey from its owners, Wild Turkey. They had purchased the Bourbon in the early 70s when the brand was growing and they needed whiskey to fill bottles in new markets. They purchased their own distillery at about that time and the Old Boone whiskey was not needed for their needs so they sold it to Julian. Julian Jr. had purchased Old Boone Bourbon to fill his decanters and bottles of Old Rip Van Winkle in the early 70s before Old Boone closed its doors, so Julian III was familiar with the product. The Old Boone distillery was in Valley Station in the southwest corner of Jefferson County, Kentucky had closed in the mid 1970’s and the whiskey Julian purchased was not 20 years old when he purchased it. He placed the barrels in the warehouse and waited. In the meantime he introduced the Van Winkle Special Reserve 12yo in 1991. Julian then created a label with the image of Pappy he had found and thus was born Pappy Van Winkle’s Family Reserve 20 years old Bourbon. Julian later told me that he was scared to death when he released the brand as he had no idea if people would drink a Bourbon that old. It did succeed because Julian III knows great whiskey that has aged well. He later released a 23 yo version of the brand using the same whiskey. When he ran out of that whiskey he started using wheated Bourbon from Stitzel-Weller to fill the bottles. There was a need to fill bottles because the brand was a success. The brand earned top honors in the ratings at the Beverage Tasting Institute of Chicago and Wine Enthusiast Magazine published the results. This high score inspired others to concentrate on promoting older versions of their brands. Things were going well but Julian knew that trouble was down the line in the future. United Distillers had closed Stitzel-Weller at the first of July 1992 and he was going to need whiskey for his brand. Not just any whiskey, but old whiskey because the youngest product he sold was ten years old. He had 10 years old Rip Van Winkle, 12 years old Van Winkle Special Reserve, 15 years old Rip Van Winkle, 20 and 23 Years Old Pappy Van Winkle’s Family Reserve brands of Bourbon and a 13 years old Van Winkle Family Reserve rye to support.
Julian told me at the time that he did not sign on with Buffalo Trace for himself, but for his son Preston. He knew that there was a chance he would be retired before the whiskey made at Buffalo Trace was ready to bottle. This was in the year 2000 and the whiskey made for Pappy then is still not ready, well sort of. After signing on with Buffalo Trace the 15 yo Rip Van Winkle was changed to 15 yo Pappy Van Winkle, but remained a 107 proof whiskey with only a bottle and label change. That whiskey is ready, but unfortunately they did not make enough to meet the demand and it is still in short supply. The whiskey for the older versions is still the barrels he purchased of Stitzel-Weller Bourbon purchased when it was still available. It is very limited in supply so that meant that in order to keep the brands alive, he had to purchase some barrels that he probably would have rejected when he had plenty of barrels to choose from. It is still a great Bourbon because Julian III has a great knowledge of how to age barrels for long term maturation and a great sense of taste and aroma.
Julian P. Van Winkle III has done a lot of hard work to create the brands he is known for today. Pappy Van Winkle’s Family Reserve is a great product in all versions, but so are all of his other expressions. I personally like the 10yo Rip Van Winkle quite a lot. I also take a minute when I drink it to remember not Pappy Van Winkle, but his son Julian Jr., who kept the family in the business and made possible the success of his son Julian III by doing so. That is one reason it irks me when people call this Bourbon “Pappy”. To me Old Rip Van Winkle will always be associated with Julian Van Winkle, Jr., a great whiskey man in his own rights.
https://bourbonveach.com/2016/12/19/pappy-101/
Persian Meow, Welcome to ROX from another shareholder.
Romaa, Thanks for posting. Important news of a clear step forward for Kevetrin.
MackG, Very well said.
Yanqui, I don't know, but it sounds more oriented toward raising cash, rather than to acquire added IP assets. EDIT: I realize we can split hairs forever making that distinction!
BRIEF-Marathon Patent Group says may offer and sell up to 750,000 shares of common stock from time to time through Northland Securities
BY Reuters
— 6:20 AM ET 01/27/2017
Jan 27 (Reuters) - Marathon Patent Group Inc ( MARA
Loading... Loading...
) :
* Marathon Patent Group Inc ( MARA ) - may offer and sell up to 750,000 shares of co's common stock from time to time through Northland Securities - sec filing Source text - http://bit.ly/2kAA4hh Further company coverage:
All we can do is keep our eyes open and report back to the group.
DM, Most everything by Zacks is garbage, IMHO. They appear to flip their ratings back and forth to try to stimulate the company covered to retain them to write a very good report and keep a high rating.
RBP, Regrettably, I do not and do not know even which "newsletter" it might be. If I somehow find it, I will post what I can.
I understand there was an investment newsletter published yesterday which suggested purchase of MARA but it wasn't the crap put out by Zacks yesterday.
News this morning about a $21 mil purchase commitment by a Chinese company. This is over 3 years and is renewable at mutual option. No idea of price per pound, gram, kilo or whatever.
Dr Zerrouk will probably award himself a $10 mil bonus for the deal. Needless to say, I'd like some performance flowing to the shareholders.
Zecotek Signs LFS Scintillation Crystal Supply Agreement Worth $21 million Over the Next 3 Years
BY Market Wire
— 3:05 AM ET 01/25/2017
SINGAPORE -- (Marketwired) -- 01/25/17 -- Zecotek Photonics Inc. (ZMSPF) , a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that it has signed a LFS scintillation crystal supply agreement with the Shanghai based company EBO Optoelectronics, to supply over $21 million worth of scintillation crystals over the next three years. The agreement stipulates that the supply of the LFS crystals will continue on a yearly basis after the initial three year period, unless otherwise agreed to by both parties. Zecotek will become the main supplier of Lutetium silicate based scintillation crystals to EBO.
"The Shanghai EBO Optoelectronics Company is a strategic customer with strong network and access to the medical imaging industry in China," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. (ZMSPF) "Recent changes to the regulatory landscape in China, regarding medical equipment imports, has caused OEMs to manufacture medical scanning devices domestically. This initial contract is a starting point and we look forward to building an even more significant business with EBO to capture a significant portion of the PET medical scanner market in mainland China."
EBO is the largest crystal array producer and supplier in China. Their arrays are used in the very fast growing domestic PET medical imaging market. Zecotek will be supplying elements of LFS to EBO as the customer. In order to meet the growing demand, Zecotek is working on the gradual expansion of its manufacturing base and capabilities, however it will be using its present facility to start the present agreement, while fulfilling, as a priority, existing orders from Zecotek's OEM partner, as well as other current accounts.
Run-away medical costs from 2010 to 2014 has caused China to take measures to modify the regulatory controls covering medical equipment in its public and private hospitals. The Chinese government uses incentives to encourage domestic hospitals to use Chinese-made medical devices as it looks to stimulate the local market and reduce soaring healthcare costs.
China's medical device market has been growing and is now ranked second largest in the world. The significant growth in the medical device market is due to both an increase in discretionary income and the world's largest aging population. The annual growth of the medical device market has been 20 percent for the past six years and is expected to continue at this pace for the next five years. With the increase in the number of OEMs manufacturing PET scanning devices, Zecotek's management team is focused on becoming a leading supplier of the key components in this market.
About Shanghai EBO Co.
Founded in 2007 and headquartered in Shanghai, EBO has more than 120 employees and 4,000 square meters of manufacturing space. Shanghai EBO fabricates and supplies crystal arrays to an extensive customer base which includes: Neusoft Medical Systems, Samsung Medical, Topgrade Healthcare, FMI Medical Systems, IHEP of CAS, Huazhong University of Science and Technology, and many domestic and foreign universities and research institutions. EBO has the highest standard processing production line and offers shaped crystal customization and crystal array assembly to end users.
About Zecotek
Zecotek Photonics Inc (ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.
This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
Image Available: http://www.marketwire.com/library/MwGo/2017/1/25/11G128367/Images/Zecotek_Product_Images_00001-e34223634addad6dbd7b1beec205a7df.jpg
For Additional Information Please Contact:
Zecotek Photonics Inc. (ZMSPF)
Michael Minder
T: (604) 783-8291
ir@zecotek.com
Source: Zecotek Photonics Inc. (ZMSPF)
More like bloodsucking ticks which try to bleed the host dry and pass along disease.
Thought I would mention an item which would affect the SP of BIVI.
In an attack "article" this week on Seeking Alpha against Cellceutix, BIVI was mentioned as a possible future target:
"Method 2: Wait for the next Ehrlich and Menon "special" to incubate
Many market participants may be unaware that yet another Ehrlich and Menon stock trades on the pink sheets: Nanoantibiotics (OTCPK:BIVI). According to Reuters, the company is run by Elliot Ehrlich and Rajah Menon, who we believe are likely related to Leo Ehrlich and Krishna Menon of Cellceutix. Although clearly shorting a $0.30 stock is problematic, we recommend investors keep a close eye on BIVI and revisit it in the event the shares ever trade to a higher price level. Mako Research certainly plans to do so.
Disclosure: I am/we are short CTIX."
While Mako's articles are entirely crap, there are people who reflexively sell ANY stock which is under attack and figure out potential validity later.
Just thought we holders should not be surprised or sell as a reflex if BIVI is attacked.
You're welcome, as always.
kpisme,
I certainly agree you are entitled to your assessment of the situation and clearly MSTX holders had not fared well under the present management.
Technically, even if there were a 1 for 100 RS (and I don't know that there would be a ratio like that), the company has the same market cap and you have the same proportion of that market cap.
As Leny explained in his article/blog, the amount MSTX is valued at in the merger is substantially higher than it was the day before anything was announced and MSTX holders have the prospect of more than a 24 percent share of ownership when all accounts are settled for cash, etc.
IMHO, both companies will be stronger together and MSTX holders get a much better management.
Fun, My folks actually had one of those, except it got winnowed out when I disposed of things selling their house. Ah, memories.
Hoping to hear at some point about BIVIs presentation in San Francisco.
Lux1, One slight correction: Aerovanc is to treat MRSA (Methicillin-Resistant Staphlococcus Aureus), rather that Pseudomonas. The CF patient indication was done to get orphan drug designation from the FDA, but it can be used to treat anyone with MRSA in the lungs.
Savara shareholder (angel investor) since 2012 here, so I do have a bias/viewpoint in this transaction which I should disclose. I am looking forward to this process.
Everyone might like to look at savarapharma.com if they want more information.